Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FOLFOX6 +/- Radiation vs 5-Fu Chemoradiation in Rectal Cancer
NCT01211210Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2010
- Primary completion
- Jun 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin in rectal cancer (3 arms), sponsored by Sun Yat-sen University. Primary endpoints: Disease Free Survival at 3 years, Objective Response Rate and 1 more. Status: unknown.
02
Drugs
oxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01211210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01211210.